Solid Biosciences Inc. (SLDB)
| Bid | 5.11 |
| Market Cap | 391.52M |
| Revenue (ttm) | 8.72M |
| Net Income (ttm) | -188.64M |
| EPS (ttm) | -3.04 |
| PE Ratio (ttm) | -1.69 |
| Forward PE | -1.14 |
| Analyst | Buy |
| Ask | 5.46 |
| Volume | 1,088,277 |
| Avg. Volume (20D) | 2,232,500 |
| Open | 5.59 |
| Previous Close | 5.59 |
| Day's Range | 5.07 - 5.63 |
| 52-Week Range | 2.88 - 15.05 |
| Beta | 2.01 |
About SLDB
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technol...
Analyst Forecast
According to 11 analyst ratings, the average rating for SLDB stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 211.89% from the latest price.
1 month ago · seekingalpha.com
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself ApartInitiation of phase 1b study, using gene therapy SGT-212 for the treatment of patients with Friedreich's Ataxia, expected 2nd half of 2025. The global Friedreich's Ataxia market is expected to grow to...
